SER

Serina Therapeutics, Inc. (SER) ESG Analysis Analysis (2026)

Invetso Score: 5.6/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.4 (Moderate)

SER’s disclosed R&D intensity is zero in the provided metrics, suggesting limited climate- or resource-efficiency investment visibility versus peers with more explicit transition spending.

The absence of reported gross profit margin and free-cash-flow margin limits evidence of environmental cost pass-through, leaving its operational footprint harder to benchmark than peers with fuller disclosure.

Debt-to-equity of 0.17 and net debt-to-EBITDA of 0.89 indicate a relatively conservative balance sheet, which can support compliance spending but does not itself signal environmental leadership.

No peer-specific emissions, energy, water, or waste data were provided, so SER’s environmental positioning can only be assessed as middling on disclosure breadth rather than performance.

Social

Score:

Zero stock-based compensation to revenue in the provided metrics implies limited use of equity-linked retention tools, which may constrain long-term employee alignment versus peers that use broader incentive structures.

The lack of disclosed R&D spend reduces visibility into workforce skill development and innovation capacity, making SER harder to compare with peers that report stronger human-capital investment signals.

Conservative leverage can reduce restructuring pressure and support workforce stability, but the available data do not show a social advantage over peers on pay, safety, or labor practices.

No metrics were provided on turnover, diversity, training, or community impact, so SER’s social profile remains neutral-to-moderate relative to better-disclosed peers.

Governance

Score:

Low debt-to-equity suggests restrained financial risk-taking, which generally supports governance discipline versus more levered peers with tighter covenant and oversight pressure.

Net debt-to-EBITDA below 1.0 indicates manageable leverage, reducing the likelihood that capital structure stress could weaken board oversight or stakeholder protections.

Zero stock-based compensation to revenue may indicate simpler compensation structures, but it also limits evidence of performance-linked governance alignment relative to peers with clearer incentive disclosure.

The provided data contain no board, audit, ownership, or controversy indicators, so governance can only be rated modestly above average on balance-sheet conservatism.

Overall Score

Score:

SER screens as a moderately positioned ESG name versus peers, with its main relative strength coming from conservative leverage and its main weakness being limited ESG disclosure breadth.

Score Driver: Conservative Leverage Offsets Otherwise Limited ESG Disclosure Visibility.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Serina Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →